No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EW240517P80000
- 0.31
- +0.20+181.82%
15min DelayClose May 10 16:00 ET
0.31High0.31Low
0.31Open0.11Pre Close2 Volume5.83K Open Interest80.00Strike Price62.00Turnover55.23%IV-8.11%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.31Time Value100Contract SizeAmericanOptions Type-0.1073Delta0.0316Gamma279.74Leverage Ratio-0.0955Theta-0.0013Rho-30.00Eff Leverage0.0195Vega
Intraday
- 5D
- 1D
News
Investors in Edwards Lifesciences (NYSE:EW) Have Seen Respectable Returns of 50% Over the Past Five Years
Edwards Lifesciences(EW.US) Officer Sells US$73,359.2 in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Lippis Daniel J. sold 857 shares of common stock on May 7, 2024 at an average price of $85.6 for a total value of $73,359.2.Source: Announcement What is statement
Express News | NYSE Order Imbalance 84071.0 Shares on Sell Side
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
Top Analyst Reports for Salesforce, BP & Southern Co.
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
NYON, Switzerland--(BUSINESS WIRE)-- Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
18
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more